[{"id":"6ec53521-6d8c-4c00-8105-0f8b45c02f79","acronym":"","url":"https://clinicaltrials.gov/study/NCT00803569","created_at":"2021-01-18T03:03:05.655Z","updated_at":"2024-07-02T16:35:34.808Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers","source_id_and_acronym":"NCT00803569","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" MUC16 • CTAG1B • CTAG2","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16 • CTAG1B • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 11/14/2008","start_date":" 11/14/2008","primary_txt":" Primary completion: 01/24/2011","primary_completion_date":" 01/24/2011","study_txt":" Completion: 01/24/2011","study_completion_date":" 01/24/2011","last_update_posted":"2023-10-04"},{"id":"e55f21e5-8dad-455d-9ad8-928753ae6727","acronym":"","url":"https://clinicaltrials.gov/study/NCT00112957","created_at":"2021-01-18T00:22:39.316Z","updated_at":"2024-07-02T16:35:34.820Z","phase":"Phase 2","brief_title":"Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer","source_id_and_acronym":"NCT00112957","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CD8 • IFNG • CTAG1B • CD4 • CTAG2","pipe":"","alterations":" ","tags":["CD8 • IFNG • CTAG1B • CD4 • CTAG2"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 12/01/2004","start_date":" 12/01/2004","primary_txt":" Primary completion: 05/01/2009","primary_completion_date":" 05/01/2009","study_txt":" Completion: 05/01/2009","study_completion_date":" 05/01/2009","last_update_posted":"2023-10-04"},{"id":"1cfc9dae-087d-4a45-888a-feae0e1a43ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT02166905","created_at":"2021-01-18T10:05:33.255Z","updated_at":"2024-07-02T16:35:54.811Z","phase":"Phase 1/2","brief_title":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission","source_id_and_acronym":"NCT02166905","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CTAG1B • CD4 • CTAG2","pipe":"","alterations":" ","tags":["CTAG1B • CD4 • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e epacadostat (INCB024360) • Hiltonol (poly-ICLC) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 10/10/2014","start_date":" 10/10/2014","primary_txt":" Primary completion: 08/20/2020","primary_completion_date":" 08/20/2020","study_txt":" Completion: 08/20/2020","study_completion_date":" 08/20/2020","last_update_posted":"2023-02-24"},{"id":"eff415a5-52c4-4898-ac00-39b39e5eb5e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT00518206","created_at":"2021-03-25T14:39:50.052Z","updated_at":"2024-07-02T16:36:01.934Z","phase":"Phase 2","brief_title":"Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma","source_id_and_acronym":"NCT00518206","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CD8 • CTAG1B • CD4 • CTAG2","pipe":"","alterations":" ","tags":["CD8 • CTAG1B • CD4 • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • NY-ESO-1 Iscomatrix • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 11/28/2003","start_date":" 11/28/2003","primary_txt":" Primary completion: 01/22/2010","primary_completion_date":" 01/22/2010","study_txt":" Completion: 01/22/2010","study_completion_date":" 01/22/2010","last_update_posted":"2022-10-25"},{"id":"76a5ebb5-de98-401a-92f2-affeb4c75df1","acronym":"LUD2002-004","url":"https://clinicaltrials.gov/study/NCT00070070","created_at":"2021-01-18T00:10:32.924Z","updated_at":"2024-07-02T16:36:02.590Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas","source_id_and_acronym":"NCT00070070 - LUD2002-004","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CTAG1B • CD4 • CTAG2","pipe":"","alterations":" ","tags":["CTAG1B • CD4 • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Leukine (sargramostim) • Tice BCG (live attenuated bacillus Calmette-Guerin)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 10/28/2003","start_date":" 10/28/2003","primary_txt":" Primary completion: 01/03/2006","primary_completion_date":" 01/03/2006","study_txt":" Completion: 09/30/2013","study_completion_date":" 09/30/2013","last_update_posted":"2022-10-12"},{"id":"29cb0858-fdb9-4eb6-80b7-ac58c084f489","acronym":"","url":"https://clinicaltrials.gov/study/NCT00199849","created_at":"2021-01-18T00:40:45.229Z","updated_at":"2024-07-02T16:36:02.775Z","phase":"Phase 1","brief_title":"NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine","source_id_and_acronym":"NCT00199849","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CD8 • CTAG1B • CD4 • CTAG2","pipe":" | ","alterations":" CTAG1B expression","tags":["CD8 • CTAG1B • CD4 • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 09/27/2004","start_date":" 09/27/2004","primary_txt":" Primary completion: 09/11/2006","primary_completion_date":" 09/11/2006","study_txt":" Completion: 09/01/2007","study_completion_date":" 09/01/2007","last_update_posted":"2022-10-10"},{"id":"acb324c0-7ea9-4e70-8f73-9c5486bc513d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00199836","created_at":"2021-01-18T00:40:44.608Z","updated_at":"2024-07-02T16:36:02.794Z","phase":"Phase 1","brief_title":"A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.","source_id_and_acronym":"NCT00199836","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CD8 • CTAG1B • CTAG2","pipe":" | ","alterations":" HLA-A2 positive","tags":["CD8 • CTAG1B • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promune (agatolimod)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 09/03/2003","start_date":" 09/03/2003","primary_txt":" Primary completion: 09/05/2005","primary_completion_date":" 09/05/2005","study_txt":" Completion: 06/06/2006","study_completion_date":" 06/06/2006","last_update_posted":"2022-10-10"},{"id":"cd953313-4922-4eb7-86f4-86fd680fb3b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00299728","created_at":"2021-01-18T01:01:31.071Z","updated_at":"2024-07-02T16:36:02.802Z","phase":"Phase 1","brief_title":"NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors","source_id_and_acronym":"NCT00299728","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CTAG1B • CD4 • CTAG2","pipe":" | ","alterations":" CTAG1B expression • CTAG2 expression","tags":["CTAG1B • CD4 • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression • CTAG2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promune (agatolimod)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 03/21/2006","start_date":" 03/21/2006","primary_txt":" Primary completion: 10/10/2006","primary_completion_date":" 10/10/2006","study_txt":" Completion: 01/10/2014","study_completion_date":" 01/10/2014","last_update_posted":"2022-10-10"},{"id":"8ea82e4e-0bda-4bce-8a02-900c33e4f243","acronym":"","url":"https://clinicaltrials.gov/study/NCT02588612","created_at":"2021-01-18T12:33:38.648Z","updated_at":"2024-07-02T16:36:24.831Z","phase":"Phase 1","brief_title":"Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT02588612","lead_sponsor":"GlaxoSmithKline","biomarkers":" EGFR • ALK • ROS1 • HLA-A • CTAG2","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • HLA-A*02 • CTAG2 expression","tags":["EGFR • ALK • ROS1 • HLA-A • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • HLA-A*02 • CTAG2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 08/10/2020","primary_completion_date":" 08/10/2020","study_txt":" Completion: 08/10/2020","study_completion_date":" 08/10/2020","last_update_posted":"2021-09-05"},{"id":"ba4fe848-c072-4266-9545-62fdc19cc6db","acronym":"","url":"https://clinicaltrials.gov/study/NCT00112242","created_at":"2021-01-18T00:22:07.954Z","updated_at":"2024-07-02T16:36:44.048Z","phase":"Phase 1","brief_title":"Immunotherapy of Stage III/IV Melanoma Patients","source_id_and_acronym":"NCT00112242","lead_sponsor":"Centre Hospitalier Universitaire Vaudois","biomarkers":" CD8 • IFNG • TNFA • CTAG1B • CD4 • MLANA • CTAG2","pipe":" | ","alterations":" HLA-A2 positive","tags":["CD8 • IFNG • TNFA • CTAG1B • CD4 • MLANA • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A2 positive"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 02/01/2004","start_date":" 02/01/2004","primary_txt":" Primary completion: 03/01/2013","primary_completion_date":" 03/01/2013","study_txt":" Completion: 03/01/2013","study_completion_date":" 03/01/2013","last_update_posted":"2020-06-18"},{"id":"81755a7f-8c1a-4b76-8aa3-b87e72987461","acronym":"","url":"https://clinicaltrials.gov/study/NCT01536054","created_at":"2021-01-18T06:29:13.362Z","updated_at":"2024-07-02T16:36:47.285Z","phase":"Phase 1","brief_title":"Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer","source_id_and_acronym":"NCT01536054","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" MUC16 • CTAG1B • CD4 • CTAG2","pipe":"","alterations":" ","tags":["MUC16 • CTAG1B • CD4 • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 08/20/2012","start_date":" 08/20/2012","primary_txt":" Primary completion: 04/21/2015","primary_completion_date":" 04/21/2015","study_txt":" Completion: 04/21/2015","study_completion_date":" 04/21/2015","last_update_posted":"2020-03-27"},{"id":"837e1307-aff9-47a1-8cb7-f58eedd670f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03697824","created_at":"2021-01-18T18:07:24.635Z","updated_at":"2025-02-25T16:08:27.486Z","phase":"Phase 1b/2a","brief_title":"Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a","source_id_and_acronym":"NCT03697824","lead_sponsor":"GlaxoSmithKline","biomarkers":" HLA-A • CTAG1B • CTAG2","pipe":" | ","alterations":" HLA-A*02 • CTAG2 expression","tags":["HLA-A • CTAG1B • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794) • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/25/2019","start_date":" 02/25/2019","primary_txt":" Primary completion: 07/18/2022","primary_completion_date":" 07/18/2022","study_txt":" Completion: 07/18/2022","study_completion_date":" 07/18/2022","last_update_posted":"2019-10-29"},{"id":"a4f3158b-5658-4f68-9525-2685c3cebcdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01706185","created_at":"2021-01-18T07:25:57.496Z","updated_at":"2024-07-02T16:37:08.469Z","phase":"","brief_title":"Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer","source_id_and_acronym":"NCT01706185","lead_sponsor":"GlaxoSmithKline","biomarkers":" WT1 • CTAG1B • PRAME • CTAG2 • MAGEA3","pipe":"","alterations":" ","tags":["WT1 • CTAG1B • PRAME • CTAG2 • MAGEA3"],"overall_status":"Completed","enrollment":" Enrollment 156","initiation":"Initiation: 01/15/2008","start_date":" 01/15/2008","primary_txt":" Primary completion: 01/15/2008","primary_completion_date":" 01/15/2008","study_txt":" Completion: 01/15/2008","study_completion_date":" 01/15/2008","last_update_posted":"2018-07-31"},{"id":"5a7da577-449f-48ff-aecb-76b7d1bdc934","acronym":"","url":"https://clinicaltrials.gov/study/NCT01522820","created_at":"2021-01-18T06:24:54.609Z","updated_at":"2024-07-02T16:37:28.702Z","phase":"Phase 1","brief_title":"Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors","source_id_and_acronym":"NCT01522820","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" ER • CTAG1B • CTAG2","pipe":" | ","alterations":" ER positive • ER negative","tags":["ER • CTAG1B • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • sirolimus • rasdegafusp alfa (CDX-1401)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 07/01/2016","primary_completion_date":" 07/01/2016","study_txt":" Completion: 07/01/2016","study_completion_date":" 07/01/2016","last_update_posted":"2016-10-04"}]